FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPRO

D.C. 20349	OMB APP	OMB APPROVAL				
	 OLID II.	2225 24				

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Name and Address of Reporting Person* Sheridan William P				<u> </u>	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [BCRX]					[(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify				ner		
(Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200					3. Date of Earliest Transaction (Month/Day/Year) 05/23/2016						X Officer (give title Officer (specify below) Senior VP - CMO						
(Street) DURHA	M N	С	27703	4	I. If Amo	endment, Da	ate of (Original Fi	ed (I	Month/Day	/Year)	6. In Line	√ Form file	ed by One F	Reporti		
(City)	(S	tate)	(Zip)														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				Saction 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4)			Beneficial Owned Fo	Form: y (D) or		Direct II Indirect E tr. 4) C	7. Nature of Indirect Beneficial Ownership				
							Code	v	Amount	unt (A) or Pi		Reported Transaction(s) (Instr. 3 and 4)			1	nstr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	version Date (Month/Day/Year) e of vative	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title an of Securit Underlyin Derivative (Instr. 3 a	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	ve es ially ng	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
Code V (A) (D) Exercisable							Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)						
Emp. Stock Option (Right to Buy)	\$3.22	05/23/2016		A		148,302 ⁽¹⁾		05/23/201	7 (05/23/2026	Common Stock	148,302	\$0	148,30	2	D	

Explanation of Responses:

1. Retention Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

/s/ Alane P. Barnes, by power of 05/25/2016 <u>attorney</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.